NRx Pharmaceuticals (NRXP) Q3 2024 earnings summary

Executive summary

• Advanced NDA filings for NRx-100 (IV ketamine) and NRx-101 (oral treatment for suicidal bipolar depression), targeting submissions by year-end 2024 and PDUFA decisions in 2025, supported by positive Phase 2b/3 data for NRX-101.

• HOPE Therapeutics, a wholly-owned subsidiary, is acquiring profitable interventional psychiatry clinics, expecting first revenues by year-end 2024 and profitability in 2025, with plans for a spin-out and public listing.

• Settled litigation with Streeterville Capital at a substantial discount, retired expensive debt, and improved capital structure, positioning for two potential drug approvals in 2025.

• Announced key leadership changes, including the appointment of Michael Abrams as CFO and Jonathan Javitt as interim CEO.

• Incorporated HOPE Therapeutics, completed its audit for a planned spin-off, and entered agreements to expand ketamine-based psychiatric treatment centers.

Financial highlights

• Net operating loss for Q3 2024 reduced to $1.6M from $6.1M in Q3 2023, a 74% improvement; nine-month net loss reduced to $16.1M from $25.8M year-over-year.

• R&D expenses for Q3 2024 decreased to $0.6M from $3.3M, and for nine months ended September 30, 2024, decreased 53% to $5.2M.

• G&A expenses for nine months ended September 30, 2024, decreased 11% year-over-year to $10.9M.

• Cash and equivalents at $1.6M as of September 30, 2024; subsequent financings provided $5.4M–$5.6M.

• Cash used in operations for the nine months ended September 30, 2024, was $8.5M, compared to $18.5M in the prior year.

Outlook and guidance

• Forecasting profitability in 2025, driven by HOPE Therapeutics revenue and projected drug sales, with first corporate revenues expected by year-end 2024.

• NDA filings for NRx-100 and NRx-101 targeted for Q4 2024, with anticipated FDA decisions (PDUFA dates) by June 2025.

• HOPE Therapeutics planned spin-out as a separate entity, with NRx, current shareholders, and new investors as owners.

• Additional financing likely needed for ongoing activities beyond 2024.